Cancer Family
Meningothelial Cell Neoplasm
CI-CAN-00000263Explore in graph →
Non-malignant65 active trials2 evidence items
- NCIt
- C6971
Loading cancer entity…
Cancer Family
CI-CAN-00000263Explore in graph →
Clinical trials
185 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03971461 | Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma | active not recruiting | Phase 2 | 32 | NYU Langone HealthOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03702309 | Liquid Biopsy Evaluation and Repository Development at Princess Margaret(LIBERATE) | recruiting | — | 2,500 | University Health Network, TorontoOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06804655 | Pharmacoscopy for Patients With Refractory Primary Brain Tumors(EViDENCE-BT) | recruiting | Phase 2 | 40 | University of ZurichOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07823985 | Preoperative Embolization for Highly Vascular Brain Tumors | not yet recruiting | N/A | 55 | Assiut UniversityOTHER | 0 | Sep 17, 2026 | clinicaltrials |
| NCT04104529 | Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department(BCB RIV) | recruiting | N/A | 350 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03180268 | Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | recruiting | Phase 3 | 163 | NRG OncologyOTHER | 5 | Sep 10, 2026 | clinicaltrials |
| NCT02847559 | Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma | completed | Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07809178 | China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm(ChTTSRUIA) | not yet recruiting | — | 608 | Cheng senOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06955169 | Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment(MOMENTUM-1) | recruiting | Phase 2 | 130 | RTOG Foundation, Inc.OTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07428616 | A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma(STELLAR-201) | recruiting | Phase 2 | 100 | ExelixisINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT02523014 | Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | recruiting | Phase 2 | 124 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04374305 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)(INTUITT-NF2) | recruiting | Phase 2 | 109 | Scott R. Plotkin, MD, PhDOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT02974127 | Multisession Radiosurgery in Large Meningiomas(MuRaLM) | completed | — | 178 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04298541 | Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07282470 | Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND(MIND) | active not recruiting | — | 210 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06557512 | Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma(SRS-AIM) | recruiting | N/A | 23 | University of California, San FranciscoOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02693990 | A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas | active not recruiting | N/A | 21 | Massachusetts General HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06014905 | Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma | recruiting | Phase 1 | 50 | Charlie Wang, MD, PhDOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07150806 | RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma | recruiting | Phase 1 / Phase 2 | 30 | Joshua PalmerOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07652762 | IN10018 in Combination With Dalpiciclib for Progressive Meningiomas | recruiting | Phase 1 | 24 | Capital Medical UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT03604978 | Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma | active not recruiting | Phase 1 / Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07533942 | A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma | recruiting | Phase 2 | 30 | Jazz PharmaceuticalsINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04427384 | Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) | recruiting | — | 600 | GT Medical Technologies, Inc.INDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05416567 | Embolization for Meningioma(e-men) | recruiting | N/A | 30 | St. Olavs HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05278208 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | recruiting | Phase 1 / Phase 2 | 65 | Nationwide Children's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07713745 | Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)(PRIME-NF2) | not yet recruiting | Phase 2 | 200 | Beijing Tiantan HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07707947 | Selumetinib for NF2-Related Schwannomatosis(ASSIST) | not yet recruiting | Phase 2 | 20 | Beijing Tiantan HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07708285 | Luvometinib in Combination With Serplulimab for NF2-Related Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Beijing Tiantan HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07398170 | Search for Circulating Tumour Cells in the Blood and/or Cerebrospinal Fluid in Patients With Recurrent Aggressive Meningiomas: Proof-of-concept Study(BIOLIMEN-1) | recruiting | N/A | 15 | University Hospital, MontpellierOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT02648997 | An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma | active not recruiting | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04638478 | PREselection of Patients at Risk for COgnitive DEcline After Radiotherapy Using Advanced MRI | active not recruiting | — | 67 | Maastricht Radiation OncologyOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07493447 | Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures | recruiting | Early Phase 1 | 30 | Eben RosenthalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06126588 | Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial(ELUMEN) | recruiting | Phase 2 | 28 | Central Hospital, Nancy, FranceOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06326190 | 177Lu-DOTATATE for Recurrent Meningioma(LUMEN-1) | recruiting | Phase 2 | 136 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jun 15, 2026 | clinicaltrials |
| NCT05576103 | Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients | recruiting | — | 300 | Jona Hattangadi-GluthOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04635657 | Cognitive Status After Removal of Skull Base Meningioma | recruiting | — | 50 | Ohio State UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07411690 | Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors(CSF-IMR) | recruiting | — | 200 | Medical University of WarsawOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04087902 | Long-Term Longitudinal QoL in Patients Undergoing EEA | active not recruiting | — | 400 | Ohio State UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07413796 | Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted Sutures(NEURO-SUTURE) | recruiting | N/A | 382 | Medical University of WarsawOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07418775 | Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma | recruiting | — | 3,000 | University of California, San FranciscoOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04305470 | Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma(MEN-301) | completed | Phase 3 | 108 | NX Development CorpINDUSTRY | 3 | May 18, 2026 | clinicaltrials |
| NCT02750371 | Effect of Irradiation of the Cavernous Sinus and the Sellar Region on Autobiographical Memory(ISOMAB) | completed | N/A | 17 | University Hospital, BordeauxOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05425004 | Cabozantinib for Patients With Recurrent or Progressive Meningioma | recruiting | Phase 2 | 24 | Baptist Health South FloridaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05636618 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors | recruiting | Phase 1 / Phase 2 | 300 | Perspective TherapeuticsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT06275919 | Regorafenib for Recurrent Meningioma (MIRAGE Trial)(MIRAGE) | recruiting | Phase 2 | 104 | Istituto Oncologico Veneto IRCCSOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03583528 | DOTATOC PET/CT for Imaging NET Patients | active not recruiting | — | 800 | British Columbia Cancer AgencyOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06668987 | A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma | completed | Phase 1 / Phase 2 | 10 | Heron Neutron Medical Corp.INDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT06466720 | Measuring and Mapping Cognitive Decline After Brain Radiosurgery(CoDeB-Rad) | active not recruiting | — | 80 | University of NottinghamOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07552233 | NK Cell Therapy for Malignant Solid Brain Tumors | recruiting | N/A | 27 | Peking University Third HospitalOTHER | 1 | Apr 27, 2026 | clinicaltrials |
Data updated 9 hours agoSource updated Sep 29, 2026source: clinicaltrials